1 / 46

ON HEART TISSUE REENGINEERING ?

Stem cell therapy and CV innovations What’s new ?. ON HEART TISSUE REENGINEERING ?. JC Chachques, MD PhD Georges Pompidou European Hospital Paris, France. Cardiac Bioassist - Cooperative Work Teams :. Olivier Schussler. Ottawa Heart Institut, Canada

lucas
Download Presentation

ON HEART TISSUE REENGINEERING ?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Stem cell therapy and CV innovationsWhat’s new ? ON HEART TISSUE REENGINEERING ? JC Chachques, MD PhD Georges Pompidou European Hospital Paris, France

  2. Cardiac Bioassist - Cooperative WorkTeams : • Olivier Schussler. Ottawa Heart Institut, Canada • Carlos Semino. MIT + Barcelona Bioengineering Center • Jorge Genovese. Pittsburgh University, USA • Jorge Trainini. Avellaneda Hospital, Argentina

  3. HEART FAILURE IN EUROPE • Heart failure is the single biggest reason for acute hospital admission. • Around 30 million people in Europe have heart failure and its incidence is increasing. • More people are living to an old age, and more are surviving a heart attack but with damage to the heart.

  4. PREVALENCE of HEART FAILURE in USA (total population: 305 millions)

  5. Evidence for cardiomyocyte renewal in humansScience 2009; 324: 98-102 Frisen J. et al, Karolinska Institut, Stockholm, Sweden • Cardiomyocytes are generated also later in life ? • Carbon-14, generated by nuclear bomb tests during the Cold War, integrated into DNA allows to establish the age of cardiomyocytes in humans • Results: cardiomyocytes renew, with a gradual decrease from 1% turning over annually at age of 25, to 0.45% at age of 75 • Fewer than 50% of cardiomyocytes are exchanged during a normal life span • Perspectives: development of therapeutic strategies aimed at stimulating this process in cardiac pathologies

  6. STEM CELL THERAPY andBIOARTIFICIAL MYOCARDIUM

  7. CARDIAC BIO-ASSIST

  8. CELLS FOR MYOCARDIAL REGENERATION • Skeletal myoblasts • Bone marrow mononuclear cells • Bone marrow mesenchymal cells • Umbilical cord cells • Adipose tissue stroma cells • Mesothelial cells (from epiploon) • Menstrual blood endometrial cells • Stem cells from the testis • Embryonic cells (pluripotents)

  9. BONE MARROW ASPIRATION

  10. DEVELOPMENT OF BIO-ARTIFICIAL MYOCARDIUM

  11. BACKGROUNDLimitations of Cellular Cardiomyoplasty • Cell bio-retention and engraftment within scar tissue is low • Mortality of implanted cells in ischemic myocardium is high • In ischemic heart disease the extracellular matrix is pathologically modified

  12. BACKGROUND 2Limitations of Cellular Cardiomyoplasty • Implanted cells lack both mechanical synchronization and electrical integration, forming « islands of tissue » Questions and risks: • Excitation-contraction coupling? • Additional excitable cells? • Proarrhythmic?

  13. RATIONALE FOR 3D CARDIAC TISSUE ENGINEERING • The efficacy and arrhythmia occurrence of stem cell therapy depends on the surviving cell number as well as the delivery route of cells • A cell-seeded epicardial scaffolds should offert additional niches for cell homing without the risk of a proarrhythmogenic substrate • Allogeneic cells should be better tolerated in a matrix « niche environment »

  14. Heart extracellular matrixCell niche + cell homing ml : muscular lacunae cl : capillary lacunae

  15. COMPONENTS OF EXTRACELLULAR MATRIX IN HUMAN HEART Collagen Type I (80%) : Ventricular chamber geometry, structural support Collagen Type III (10%): Role in transduction of myocyte shortening during systole

  16. EXTRACELLULAR MATRIX IN ISCHEMIC HEART DISEASE Collagen Type I :Decreases from 80% to 40% Collagen Type III : Increases from 10% to 35% RESULTS : Ventricular dilatation, systolic + diastolic dysfunctions

  17. COLLAGEN TYPE I MATRIX (Pangen 2, France)lyophilised, bovine collagen, 5 x 7 x 0.6 cm

  18. DEVELOPMENT OF ARTIFICIAL MYOCARDIUM • Collagen matrix (type I) • 3D and Biodegradable • Seeded with stem cells

  19. Collagen Matrix without cells seeded with cells

  20. Confocal Microscopy3D matrix + cells

  21. MATRIX GRAFTED ON EPICARDIUM MATRIX

  22. PRECLINICAL STUDIESPublished in Tissue Engineering 2007; 13:2681-7Cell-seeded collagen matrix - 2 Mo Follow-up

  23. BIOARTIFICIAL MYOCARDIUM « MAGNUM » Clinical Trial M yocardial A ssistance by G rafting a N ew bioartificial U pgraded M yocardium

  24. Rationale Associate a procedure for myocardial and extracellular matrix regeneration, i.e. Cellular cardiomyoplasty + Collagen scaffold grafting

  25. Cellular CMP + Cell Seeded Matrix

  26. Clinical Collagen Matrix Implantation

  27. MAGNUM Clinical Trial RESULTS

  28. Functional Outcomes: 1 year follow-up NYHA Class p =0.005 Baseline End FU

  29. LV Ejection Fraction (%) p = 0.04 Echocardiographic Study

  30. LV End Diastolic Volume (mL) p = 0.03 Echocardiographic Study

  31. LV FILLING Doppler-derived mitral deceleration time (ms) p = 0.01 DIASTOLIC FUNCTION

  32. Scar Area Thickness (mm) p = 0.005 Echocardiographic Study

  33. Cellular CMP + MatrixRadioisotopic SPECT sestamibi studiesPreop 12 Months

  34. MAGNUM CLINICAL TRIALCONCLUSIONS • REDUCES THE SIZE AND FIBROSIS OF INFARCT SCARS • MINIMIZES GLOBAL VENTRICULAR DILATATION • IMPROVES DIASTOLIC FUNCTION • INCREASES MYOCARDIAL WALL THICKNESS • INDUCES MODULATION OF EXTRACELLULAR MATRIX

  35. MAGNUM CLINICAL TRIALCONCLUSIONS • The implanted matrix contributed to generate the “adequate niche” for native, transplanted and migrating stem cells

  36. FUTURE MATRIX IMPROVEMENTS • Crosslinking angiogenic growth factors • Prolong absorption delay by nanotechnologies and additional chemical - physical crosslinking • Stem cell preconditioning : hypoxic conditions (5%) during cultures in-vitro electrostimulation

  37. Nature Clin Pract Cardiovasc Med 2009; 6: 240-9 Use of arginine-glycine-aspartic (RGD) acid adhesion peptides coupled with a new collagen scaffold to engineer a myocardium-like tissue graft Schussler O, Coirault C, Louis-Tisserand M, Chachques JC, Carpentier A, Lecarpentier Y

  38. Frontiers in Bioscience. 2009; 14: 2996-3002 Cardiac pre-differentiation of human mesenchymal stem cells by electrostimulation Genovese J, Spadaccio C, Schussler O, Carpentier A, Chachques JC, Patel AN

  39. Biomaterials. 2009; 30: 1156-65 The effect of self-assembling peptide nanofiber scaffolds on mouse embryonic fibroblast implantation and proliferation Degano IR, Quintana L, Semino C, et al.

  40. A prototypic synthetic extracellular matrix • Molecular designed material • Chemically defined • Synthetic process • Highly similarity to natural ECMs • structure: nano-scale fibers • self-assembling process • biologically permissive • non-competition with natural ECM • biodegradable • Mechanical properties for soft tissues • Modification control Building up properties • Transient scaffold • Injecting biological material

  41. A generic peptide scaffold network Peptide nanofibers = 10-20 nm Scaffold pore size = 50-200 nm

  42. RECATABI PROJECT - European Union

  43. RECATABI PROJECT - European Union

  44. CARMAT ( Carpentier - Matra )Artificial Heart

More Related